Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
about
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancersPrevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.New agents for the management of resistant metastatic breast cancer.Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers.Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.Are We Ready to Use ESR1 Mutations in Clinical Practice?Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.Chromatin reprogramming in breast cancer.Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancerUnraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer
P2860
Q38631621-2944421D-E75C-4830-99A3-257F97E4F7E2Q40503471-3F59AFBF-48D7-4DD8-836E-77BDB810EEC1Q41305086-897167A4-78EB-4BD1-B83D-A9F03D68534DQ47163200-0997E060-1CC6-45C0-B0B5-990217860957Q47807006-990A4FB3-47C3-46D4-A10A-094ACBF25F1EQ48240854-B4276FBA-0096-40D0-87CA-1A5B51D86D06Q48349892-27676AD2-FB6F-4B43-8FB5-12E145F85D33Q49724900-D7701BFB-F91D-49D9-9DF2-452577C29741Q49805743-1FEED20E-12F0-4966-99CE-0FC8F5290124Q49885951-BC7FDE2F-D8C3-4DBC-973F-717B23B87DD5Q50040433-5EC15BDD-07E6-4DD6-94D6-B2DD966E1ABCQ50147171-118D84BA-05DB-4133-97D8-B07F0037A2C7Q52310380-48BC847A-34FA-4C2C-853C-B77F1A485211Q53684285-20E0FB8F-8088-4967-8819-2C6957C8D120Q53702674-667FD923-F231-4A0C-87E4-5DBE24CB9784Q55710176-6A2DB9BD-BBCD-41C4-B695-158943B0EEC0Q57106904-53ECA6CA-5E7E-48B3-A7C9-EB28F364CB07Q58803565-154F5326-8322-443A-B5C0-D86C6D79C7A8
P2860
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
@en
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
@nl
type
label
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
@en
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
@nl
prefLabel
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
@en
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
@nl
P2093
P2860
P1433
P1476
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
@en
P2093
Aaron Smith
Anne Marie Mazzola
Anne U Goeppert
Christopher Morrow
Elisa De Stanchina
Geoffrey Greene
Hazel Weir
Joanne Wilson
John A Katzenellenbogen
José Baselga
P2860
P304
P356
10.1158/2159-8290.CD-15-1523
P577
2016-12-16T00:00:00Z